Proteasome Inhibitor News and Research

RSS
Carfilzomib therapy shows promise for pre-kidney transplant patients

Carfilzomib therapy shows promise for pre-kidney transplant patients

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

NIH-funded investigators develop therapeutic compound effective against malaria

NIH-funded investigators develop therapeutic compound effective against malaria

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Three-drug combination produces better results in multiple myeloma patients

Three-drug combination produces better results in multiple myeloma patients

Drug combination shows promise in patients with newly diagnosed multiple myeloma

Drug combination shows promise in patients with newly diagnosed multiple myeloma

Researchers restore missing repair protein in skeletal muscle of patients with muscular dystrophy

Researchers restore missing repair protein in skeletal muscle of patients with muscular dystrophy